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Fanconi anemia (FA) is a rare inherited syndrome with diverse clinical symptoms including developmental defects, short stature,
bone marrow failure, and a high risk of malignancies. Fifteen genetic subtypes have been distinguished so far. The mode of
inheritance for all subtypes is autosomal recessive, except for FA-B, which is X-linked. Cells derived from FA patients are—by
definition—hypersensitive to DNA cross-linking agents, such as mitomycin C, diepoxybutane, or cisplatinum, which becomes
manifest as excessive growth inhibition, cell cycle arrest, and chromosomal breakage upon cellular exposure to these drugs.
Here we provide a detailed laboratory protocol for the accurate assessment of the FA diagnosis as based on mitomycin C-
induced chromosomal breakage analysis in whole-blood cultures. The method also enables a quantitative estimate of the degree of
mosaicism in the lymphocyte compartment of the patient.
1. Introduction
Fanconi anemia (FA) is a cancer-prone chromosomal insta-
bility disorder with diverse clinical symptoms (Table 1)
[1]. Because of its rarity and variable presentation FA may
be heavily underdiagnosed [2, 3]. Clinical suspicion of
FA is mostly based on growth retardation and congenital
defects in combination with life-threatening bone marrow
failure (thrombocytopenia and later pancytopenia), which
usually starts between 5 and 10 years of age. However, the
clinical manifestations are highly variable, while some of
the symptoms may overlap with those observed in other
syndromes, making a reliable diagnosis on the basis of
clinical features virtually impossible (Table 1). Even patients
presenting with a number of “typical” FA symptomsmay not
be suﬀering from FA. Cells derived from true FA patients
must exhibit a hypersensitivity to chromosomal breakage
induced by DNA cross-linking agents such as mitomycin C
(MMC), diepoxybutane (DEB), or cisplatinum.
Indications to test for FA are typical congenital abnor-
malities with/without thrombocytopenia and/or marrow
failure. However, congenital abnormalities may be absent,
while isolated thrombocytopenia may be the only presenting
symptom. In all children with aplastic anemia FA should
be tested as the possible underlying disease. In children
and adults with cancer and an unusual response to DNA-
damaging agents such as chemotherapy or radiotherapy
(severe skin reactions or mucositis, longlasting aplasia), FA
should also be tested for. Similarly, in adults with carcinomas
(typically located in the mouth/esophagus or anogenital
region) at relatively young age, FA should be considered.
Cancer or leukemia may be the first symptom of FA, while
congenital abnormalities and marrow failure may be absent
altogether, the latter especially in cases with hematopoietic
mosaicism [4–6].
The cellular phenotype typical for FA is ascertained using
phytohaemagglutinin-stimulated whole-blood (T lympho-
cyte) cultures. Although it has been considered the gold
standard for diagnosing FA, the test is not 100% specific.
A few cases of Nijmegen breakage syndrome have been
reported to give a false positive result [7–9], which can
be excluded by screening the NBS1 gene for mutations.
In addition, patients suﬀering from the cohesinopathies
Roberts syndrome (mutated in ESCO2) and Warsaw break-
age syndrome (mutated in DDX11) may score positive in
the test [10]. Additional “atypical FA” or “FA-like” patients
have been reported as case reports [11, 12]. Somewhat
controversially, the “FA-like” patient found to be mutated in
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Table 1: General features and symptoms associated with Fanconi anemia.
Birth prevalence 0.5–2.5 per 105 newborns; varies with ethnic background.
Mode of inheritance Autosomal recessive (>98%) and X-linked (∼1-2%).
Carrier frequency
Traditional overall estimate: “1/300 worldwide.” Needs reassessment according to
subtype and ethnic background.
Congenital abnormalities∗
Radial ray abnormalities (aplastic or hypoplastic radii and absent or extra thumbs)
and other skeletal abnormalities; small head circumference; abnormal shape of the
ears; microphthalmia; ectopic or horse-shoe kidney; hypogonadism; heart
abnormalities; intestinal or anal atresia.
Other somatic
abnormalities∗
Short stature/retarded growth; reduced fertility; skin pigmentation
abnormalities (hyperpigmentation, cafe´-au-lait spots); deafness. Endocrinopathy
aﬀecting the pancreas (diabetes mellitus), growth hormone deficiency, and
hypothyroidism; early menopause.
Hematological symptoms
Bone marrow failure or aplastic anemia typically starting at 5–10 years with
thrombocytopenia. Exception: D1 and N patients may die before that age from
AML or other childhood solid tumors (such as medullo- or nephroblastoma).
Cancer risk
800-fold increased risk of AML, mostly occurring at age 5–15 years, typically after
the onset of marrow failure. At older ages there is a similarly increased risk of solid
tumors, mainly carcinomas of the head and neck or oesophagus, as well as, in
females, the vulva and vagina. D1 and N patients typically develop malignancies
during early childhood (<5 years).
Overlapping syndromes∗∗
Inherited bone marrow failure syndromes: Dyskeratosis congenita,
Diamond-Blackfan anemia, Shwachman-Diamond syndrome, severe congenital
neutropenia, thrombocytopenia absent radii (TAR) syndrome, amegakaryocytic
thrombocytopenia.
Other overlapping syndromes: Baller-Gerold syndrome, Nijmegen breakage
syndrome, Rothmund-Thomson syndrome, Roberts syndrome, Warsaw Breakage
syndrome, DK-phocomelia, VACTERL hydrocephalus syndrome, Wiskott-Aldrich
syndrome.
∗Many symptoms show highly variable penetrance. In a sizable proportion of patients (ca. 30%), congenital abnormalities may be absent altogether. Features
in bold are most consistently associated with the FA phenotype.
∗∗For an overview of the overlapping inherited bone marrow failure syndromes, see [5, 25]. For the other overlapping syndromes, the reader is referred to
the OMIM database. Three overlapping syndromes may score positive in a chromosomal breakage test (italic): Nijmegen breakage syndrome [7–9], Roberts
syndrome, and Warsaw Breakage Syndrome [10].
RAD51C has been assigned to a distinct genetic FA subtype
(FA-O) [13].
Approximately 80% of the patients referred for FA
diagnostic testing because of bone marrow failure score
negative in the chromosomal breakage test. These “true
negatives” have other causes of marrow failure and most
often represent cases with acquired aplastic anemia.
Lymphocyte mosaicism occurs in a sizable proportion of
FA patients (estimated at 10–30%) and is caused by sponta-
neous genetic reversion at the disease locus in hematopoietic
progenitor cells; the reverted cells may (partially) correct
the bone marrow failure [14–18]. In most of these cases FA
can still be diagnosed by testing peripheral blood, since a
portion of the cells will still show hypersensitivity to cross-
linking agents. Occasionally, the percentage of reverted cells
has reached such a high level as to produce a false negative
diagnosis. In such cases cross-linker sensitivity may be tested
in skin fibroblasts, which are not known to be aﬀected by
mosaicism. After a positive breakage test result has been
obtained, screening for mutations in the known FA genes is
warranted.
Laboratory studies have revealed as many as 15 distinct
“complementation groups” or genetic subtypes: FA-A, -B,
-C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, and -P [13, 19–
21]. For all subtypes known to date the disease genes have
been identified. Global relative prevalences are diﬃcult to
estimate, as the values may diﬀer considerably depending
on the ethnic background, due to founder eﬀects. All FA
genes are localized on autosomes, except FANCB, which is X-
linked and subject to X inactivation in female carriers [22].
These two diﬀerent modes of inheritance have important
consequences for the counseling of FA families.
Recognition of FA as a chromosomal instability disorder
was originally based on chromatid-type aberrations spon-
taneously occurring in standard cytogenetic preparations.
However, this phenomenon was later found to be highly
variable and considered not reliable for diagnostic purposes.
After the discovery of an extreme sensitivity of FA cells to
the chromosome-breaking eﬀect of the cross-linking agents
mitomycin C (MMC) [23] and diepoxybutane (DEB) [24],
this feature has become routinely utilized to diagnose FA by
a “chromosomal breakage test.” In this test, T lymphocytes
in a peripheral blood sample are cultured in the presence of
a cross-linking agent, after which chromosomal aberrations
are quantified in metaphase spreads. Numerous variations
of the test are used in the various cytogenetic laboratories,
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with significant diﬀerences in exposure times and drug
concentrations. Also, the ways in which data are evaluated
are diverse. We have encountered opposite conclusions from
diﬀerent laboratories based on the very same primary data
set, due to a lack of experience in performing the test and
evaluating the resulting data. Evidently, there is a great need
for a clearly described reliable protocol for the accurate
diagnosis of FA patients.
2. Methods and Results
Here we describe a laboratory protocol that has evolved
during 30 years of experience and which we can recommend
for the unambiguous diagnosis of the vast majority of FA
patients, including patients with hematopoietic mosaicism.
The test is based on the 72 hour whole-blood cultures as
routinely applied in cytogenetics laboratories to make chro-
mosomal preparations for karyotypic analysis. Metaphase
spreads are Giemsa-stained (not banded) and analyzed
for microscopically visible chromatid-type aberrations. For
technical details the reader is referred to the appendices.
Laboratories that are not set up to do this type of assay or
have no experience with diagnosing FA on a regular basis
should be advised to refer to a laboratory where the test is
applied on a routine basis, rather than attempting to carry
out a “similar” test that is considered a plausible alternative.
The test might be omitted if a proband belongs to an ethnic
population with a high carrier frequency for a specific FA
gene mutation. Demonstrating this mutation in the proband
would be diagnostic for FA, although the result may not
provide information about possible mosaicism.
3. Discussion
It should be pointed out that, even though we have chosen to
use MMC as the cross-linking agent, DEB is used in a widely
accepted alternative protocol [1, 26–28]. Pros and cons for
using the various cross-linking agents are further discussed
in the appendices.
Cell cycle analysis via flow cytometry has been used as
an alternative way to diagnose FA in skin fibroblasts [29],
amniocytes [30], and peripheral blood mononuclear cells
[31–34]. This test is based on the fact that cells from FA
patients are hypersensitive towards DNA cross-linking agents
and tend to be delayed and arrested with a 4c DNA content
in the late S/early G2 phase of the cell cycle [35–38]. With
the exception of overt leukemia and complete lymphocyte
mosaicism, the cell cycle test reliably diﬀerentiates between
FA and non-FA blood samples, including non-FA patients
with aplastic anemia, Nijmegen breakage syndrome, Roberts
syndrome, Baller-Gerold syndrome, VACTERL, and other
thrombo- and erythropenia syndromes, as these conditions
lack elevated G2-phase cell fractions [39]. For details of the
cell cycle assay, readers are referred to the published protocols
[39, 40].
FANCD2 western blotting is another alternative proce-
dure to diagnose FA [40]. With this method stimulated T
lymphocytes are tested for the occurrence of the ubiquiti-
nated isoform of FANCD2, which readily reveals FA in cases
where this isoform is lacking (subtypes A, B, C, D2, E, F, G,
I, L, and M). This is a convenient alternative for diagnosing
>90% of all FA patients. A disadvantage is that the subtypes
with a defect downstream of FANCD2 ubiquitination (D1,
J, M, N, O, P and possibly new subtypes) are not diagnosed
as FA. In addition, true FA cases with significant lymphocyte
mosaicism may also be missed by FANCD2 western blotting.
Why would a relatively laborious breakage test still be
relevant now that next-generation sequencing (NGS) is
available to determine mutations in FA genes? Two types of
result fromNGSwould require assessment of the cross-linker
sensitive cellular phenotype. First, unclassified sequence vari-
ations may be identified, whose pathogenic status remains
uncertain until functionally tested. Second, if all known
FA genes were found to be unaﬀected by mutations, a
putative new FA gene may be found mutated. Proof of
identity as a new FA gene requires the demonstration of
cellular hypersensitivity to cross-linking agents and some
form of functional test where introduction of a wild-type
allele should correct the phenotype.
Appendices
A. Laboratory Protocol for Testing
MMC-Induced Chromosomal Breakage
A.1. Materials
(1) Heparinized venous blood (≥2mL; preferably freshly
drawn, or kept at room temperature for no longer
than 48 h) from the patient to be tested and from a
healthy control.
(2) RPMI or Ham’s F10 culture medium, including 15%
fetal bovine serum, streptomycin, penicillin, and phy-
tohemagglutinin, as utilized in standard cytogenetic
whole-blood cultures.
(3) Mitomycin C (MMC, mol. wt. 334.33, Kyowa Hakko
Kogyo Co., Ltd., Tokyo, Japan, clinical grade), avail-
able in vials of 2mg with 48mg NaCl, to be stored at
4◦C.
(4) Materials for the preparation of metaphase spreads.
A.2. Culturing and Cytogenetics Methods
(1) Prepare a stock solution of MMC at 1.5mM
(0.5mg/mL) by adding 4mL sterile water per vial;
this solution is stable for 3 months at 4◦C. It is
mandatory “not” to freeze the MMC stock solu-
tion, since—upon thawing—an unknown quantity
of MMC appears as crystals that do not readily
redissolve.
(2) Prepare whole-blood cultures from the patient and
the healthy control, as usual for a standard cytoge-
netic analysis [25]. You need 4 cultures for the patient
and 4 for the healthy control, who should not be
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a brother or sister of the patient. Initiate the cultures
by adding 0.5mL blood to 4.5mL complete medium.
(3) Add, at the time of culture initiation, to each set of 4
cultures: 0, 50, 150, and 300 nM MMC, as indicated
below.
(i) Dilute 1 part stock solution plus 9 parts H2O
→ solution A (150 µM).
(ii) Dilute 1 part solution A plus 4 parts H2O →
solution B (30 µM).
(iii) Add to the 4 cultures from each individual:
(a) 50 µL saline → final concentration: 0 nM,
(b) 8.3 µL solution B → final concentration:
50 nM (optional),
(c) 25 µL solution B → final concentration:
150 nM,
(d) 50 µL solution B → final concentration:
300 nM.
N.B. If insuﬃcient blood should be avail-
able, the 50 nM cultures may be omitted.
(4) Harvest at 72 h, after colcemid treatment during the
last 40min (Sigma, demecolcine final concentration
200 ng/mL). Prepare at least 4 microscope slides for
every culture; make more slides if mitotic activity
is low, to end up with at least several hundreds
of metaphases, accounting for the possibility that a
large proportion will later be judged unacceptable
for microscopic analysis. Stain with Giemsa only. Do
not apply any banding technique. Store remaining
suspension at –20◦C, for future use, if necessary.
A.3. Scoring the Aberrations. It is important to realize that
quantification of chromosomal aberrations shows significant
diﬀerences between laboratories. From a comparative study
it appeared that the most important source of disagreement
was about whether particular aberrations really existed or
not, and about the definition and scoring of gaps [41].
It is therefore mandatory to score metaphases from coded
slides (“blind”), that is, without knowing the identity of the
preparation you are scoring. Do not score more than 25 cells
per slide. This is to reduce the possibility of biased scoring,
which would result from inspecting too many metaphases
from the same slide. To obtain suﬃcient statistical power
of the breakage data, attempt to find and score at least 50
scorable metaphases per culture (to be scored from at least
two slides).
A.3.1. Coding and Organizing the Slides before Scoring. After
staining, divide the slides into two equal sets per culture, each
set containing 2, 3, or more slides (depending on metaphase
yield) to allow the analysis of 25 scorable metaphases per set
(see also Appendix A.2, point 4). Cover the unique identifier
information on the slide with a piece of nontransparent tape.
Write a random code on each set of slides and distinguish
multiple slides within a set by adding A, B, C, and so forth.
Example 1. for every culture, you end up with 4 slides or
more (depending on the mitotic index), coded as follows:
[random code-1]A, [random code-1]B, and so forth; [random
code-2]A, [random code-2]B, and so forth.
The scoring of metaphases (see below) starts with slide
[random code-1]A until 25 metaphases have been examined.
If fewer metaphases were found on the slide, proceed with
slide [random code-1]B, and so forth, until the desired
number of metaphases (in our case: 25) have been scored.
Follow the same procedure for [random code-2]A, -B, -C, and
so forth. After finishing the scoring of all preparations, the
codes are uncovered and the two data sets from the various
cultures are combined to provide results per 50 metaphases.
A.3.2. How to Score Chromosomal Aberrations. Systematically
select the metaphases to be analysed: search, at 400x
magnification, for metaphases judged suitable for evaluation
of chromosomal integrity. To avoid a bias for relatively
undamaged metaphases, do not at this stage select on the
basis of “quality,” since “nice-” looking metaphases tend
to have fewer aberrations. Rather, every next metaphase
encountered should—in principle—be scored, unless it
must be rejected because it fails to meet the observer’s
criteria for adequate spreading, state of condensation of the
chromosomes (not too long or too short), adequate staining
and morphology (clearly recognizable chromosomes with
clearly visible centromeres), and adequate ploidy. When a
metaphase meets these criteria, that metaphase must be
scored, at 1000x magnification, even if “diﬃcult” aberrations
are subsequently encountered. However, be sure to score only
the really convincing aberrations while ignoring the uncon-
vincing ones. Distinguish the following types of aberration:
(1) chromatid gap, an interruption in the staining of
a chromatid 1-2 times the width of that chromatid
(Figure 1(a));
(2) chromatid break, where the interruption is more
than 2 times the width or where the broken piece of
chromatid appears dislocated, as in Figure 1(b);
(3) triradial chromosome, an interchange figure presum-
ably having resulted from the misrepair of two breaks
in two distinct chromosomes (Figure 1(c));
(4) quadriradial chromosome, an interchange figure
resulting from the misrepair of two broken chro-
matids in diﬀerent chromosomes (Figure 1(d));
(5) Other chromatid interchange figures, such as illus-
trated in Figure 1(e).
Chromosome-type changes, such as dicentrics, acentric
fragments, and ring chromosomes, may be recorded, but
these aberrations, which are extremely rare with the protocol
used, should not be included in the final analysis.
A.3.3. How to Record the Aberrations. The aberrations
observed should be recorded with the coordinates of the
metaphase, so that aberrant metaphases can be retrieved
whenever considered necessary. This can be achieved man-
ually, or with the help of an automated metaphase finder
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(a) (b) (c) (d)
(e)
(f) (g) (h)
Figure 1: Examples of chromosomal aberrations typically observed in a MMC-induced chromosomal breakage assay to diagnose FA. (a)
Chromatid gap (broken piece in place); (b) chromatid break (broken piece dislocated); (c) chromatid interchange figure (“triradial”); (d)
chromatid interchange figure (“quadriradial”); (e) other chromatid interchange figures. In the eventual analysis, (a) and (b) are counted as
one, (c) and (d) as two break events. The left figure in (e) is counted as 8 break events (5 centromeres plus 3 open breaks); the right figure
is equivalent to a quadriradial as in (d) (2 break events), in which two break points remained disconnected. (f), (g), and (h), are examples
of nonconvincing “aberrations” that should be ignored in the analysis. (f) A gap that is not 100% convincing and should be ignored. (g) An
association of 3 acrocentric chromosomes showing “satellite association”, not to be confused with a triradial, as in (c). (h) Two overlapping
chromosomes, not to be confused with a true quadriradial, as in (d).
equipped with a customisable scoring sheet for the eval-
uation of chromosomal aberrations, such as developed by
Metasystems, Altlussheim, Germany. A sheet developed for
manual evaluation may be obtained from the authors, upon
request.
A.4. Analyzing the Results
A.4.1. Converting Aberrations into Break Events. The ratio
between gaps/breaks (“open breaks”) and interchange-type
aberrations (“wrongly repaired breaks”) may vary consider-
ably. Therefore, for the final evaluation, all aberrations are
converted into “break events”, which represent the primary
type of aberration in an FA cell.
Chromatid gaps or breaks are counted as single break
events, tri- and quadriradials as two break events each. Other
interchange figures are converted into the minimum number
of breaks required for their theoretical reconstruction; in
practice, this means that the number of centromeres in
an interchange figure is added up to the number of open
breaks/gaps, see Figure 1. To avoid spending too much time
on reconstructing complex interchange figures, cells showing
more than 10 break events are not further quantified and are
included in a common category “≥10 breaks/cell”. Evaluate
the data from a histogram, in which the percentage of cells is
plotted against the number of break events/cell, as illustrated
in Figure 2.
A.4.2. Evaluating the Results: “FA”, “Non-FA”, or “Mosaic FA”.
In cultures from a typical full-fledged FA patient a substantial
proportion of the cells should show chromosomal breakage
already at 50 nM MMC (Figure 2). At 150 nM MMC, the
majority of cells should be aberrant, while at 300 nM no
undamaged cells should be left and most cells should be
in the category “≥10 breaks/cell”. In contrast, cultures from
the healthy control should hardly or not be aﬀected, except
at 300 nM, where typically 30% of the cells may show 1 to
≤5 break events/cell.
In cultures from FA patients with lymphocytemosaicism,
two cell populations are distinguished at 300 nM MMC,
one behaving like typical FA cells, that is, showing
≥10 breaks/cell, and one behaving like healthy controls,
that is, largely represented by the categories 0-, 1-, and 2-
breaks/cell.
In the event of a positive result (FA or mosaic FA), all
asymptomatic sibs of the patient should be tested as well,
which is particularly important if the sibs are considered
as potential stem cell donors. A positive result indicative
of FA should immediately be evident from the histogram
(Figure 2). If statistical analysis is considered necessary to
“prove” a dubious diagnosis, the diagnosis “FA” is likely to
be wrong.
If the result indicates “non-FA”, an important question
is whether the MMC concentration was correct. This is
another reason why the highest concentration (300 nM) is
included, since at this concentration the healthy control
should show significantly elevated breakage. The diﬀerence
between treated and untreated control cultures may be tested
by comparing the percentages of aberrant metaphases, using
a 2-sample Chi-square test. If the healthy control should fail
to show a clear response to the MMC at 300 nM, the result
“non-FA” is inconclusive and the test should be repeated.
B. Technical Notes and Comments
B.1. Breaks and Gaps. In the 1980s the distinction between
chromatid gaps and breaks has been the subject of much
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Figure 2: Evaluation of MMC-induced chromosomal breakage in stimulated T lymphocyte cultures. Upper row: healthy control; middle
row: FA patient; lower row: mosaic FA patient. The healthy control shows breakage only at 300 nM, where the FA patient shows massive
breakage (no normal cells present). Mosaicism is evident from the two highest concentrations of MMC, where there are still normal cells
present next to cells showing an FA-like breakage rate (>10 breaks/cell). A crude estimate of the proportion of reverted T cells in this mosaic
patient would be ∼40%.
discussion, the issue being whether a gap represented a
true double-stranded break in the DNA of a chromatid. A
problem during the evaluation of aberrations is to decide
which gap-like feature should be scored as a true aberration.
A consensus was reached by accepting an aberration as a gap
if the discontinuity in the staining of a chromatid is at least
as wide as the width of the chromatid. If wider than twice
the width of the chromatid, the aberration may be scored
as a break [42]. If the “broken” piece appears dislocated the
aberration is always scored as a break. If the interruption
is considered doubtful, it should be ignored (Figure 1);
this holds for all other aberrations that appear not entirely
convincing.
The main reason to distinguish between chromatid gaps
and breaks is that their biological impact may be diﬀerent;
conclusions based on significant diﬀerences in the frequency
of gaps only, should be viewed with caution.
B.2. Saving Time on the Breakage Test
B.2.1. Finding Metaphases. In cases of low mitotic activity
considerable time may be gained by utilizing a metaphase
finding apparatus, which can perform unattendedmetaphase
searches on multiple slides. Such apparatus may also
be equipped with software for chromosomal aberration
scoring, see for example, http://www.metasystems-interna-
tional.com/
B.2.2. Scoring Aberrations. To save time, the scoring process
may be divided into phases. Score first the cultures exposed
to 0 and 300 nM MMC, which may already give you an
unambiguous answer.
(1) The diagnosis “FA” is warranted if all cells from the
proband contain multiple aberrations, whereas the
majority of the control cells is normal.
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(2) A result excluding FA should be based on a modest
but significantly elevated breakage level at 300 nM
MMC, both in the proband and in the healthy
control.
If there are too few evaluable metaphases, or if there is
an indication of mosaicism, score the samples exposed to
150 nM, and—with again too few metaphases present—
the 50 nM samples as well. If, however, the 300 or 150 nM
cultures have provided a conclusive answer, the 50 nM
cultures may be skipped.
Some laboratories score only chromatid interchanges
(often referred to as “radials”) as aberrations, while ignoring
chromatid breaks and gaps. Even though this is a consider-
able time saver, there are several disadvantages. First, with
full-fledged (nonmosaic) FA patients “normal” cells (i.e.,
cells without interchange aberrations) are still observed at the
higher MMC concentrations, leading to a false impression
of mosaicism. Second, at the highest MMC concentration
the aberration rate in the control does not reach statistical
significance, which eliminates the internal check for drug
activity. Third, chromatid interchanges are generated from
chromatid breaks by an unknown joining mechanism, the
precise nature of which is unclear, while variations in this
process will aﬀect the ratio between breaks and interchanges.
As this ratio may vary from patient to patient, some FA
patients might go unrecognised when scoring chromatid
interchanges only.
B.2.3. High-Level Mosaicism. With the protocol described,
most patients with mosaicism will be correctly diagnosed as
FA, because even a minor proportion of FA-like lymphocytes
will show up in the ≥10 breaks/cell category. When no
FA cells can be detected in a patient with a “compelling”
clinical phenotype, fibroblasts can be used to establish the
diagnosis. We have encountered several FA patients whose T
lymphocytes’ response was indistinguishable from that in the
healthy control, but whose skin fibroblasts’ response clearly
revealed the cellular FA phenotype (see, e.g., [6, 15]).
Breakage Test Using Fibroblasts. AddMMC (50 nM) or saline
to either of two 80 cm2 tissue culture flasks containing 1-2×
106 freshly trypsinized fibroblasts (preferably fewer than 8 in
vitro passages) from the following individuals: (1) the patient
to be tested, (2) a healthy control, and (3) a known FA patient
(positive control). After 48 h at 37◦C, harvest the cultures
by trypsinization, following colcemid treatment for 45min,
and prepare chromosome slides. Code the slides and score
for aberrations (50 cells per culture). Typical results are as
follows.
“Control (non-FA) fibroblasts”, untreated: 3% aberrant
cells (0.03 breaks/cell); MMC-treated: 13% aberrant
cells (0.2 breaks/cell).
“FA fibroblasts”, untreated: 7% aberrant cells
(0.07 breaks/cell); MMC-treated: 95% aberrant cells
(7 breaks/cell).
B.2.4. Alternative Cross-Linking Agents. Several other DNA
cross-linking agents, besides MMC, have been used to
demonstrate the hypersensitive phenotype of FA cells, for
example, diepoxybutane (DEB), and cis-diamminedichlo-
roplatinum(II) (cisplatin). DEB is on the Special Health
Hazard Substance List because it is a (volatile) carcino-
gen that should be handled with great caution. DEB is
hygroscopic and—upon contact with water—slowly loses
activity, with a half-life of approximately 4 days, because
it hydrolyzes into 1,2,3,4-tetrahydroxybutane, a compound
with no cross-linking activity. DEB is commercially available
from Sigma/Aldrich. Since diﬀerent batches may vary in
activity, comparative testing is required, since relatively small
diﬀerences may lead to incorrect conclusions regarding
mosaicism in a patient (compare the standard concentration
of 0.1 µg/mL with 0.15 µg/mL in [14]). MMC, which—as
a clinically approved chemotherapeutic agent produced by
Kyowa Hakko Kogyo (not by Sigma)—is under rigorous
quality control and is stable when stored in the vials provided
by the manufacturer. A similar argument would favour
the use of cisplatin, which is also clinically approved, over
DEB as the diagnostic reagent for FA. On the other hand,
provided the reagents are properly handled, DEB, MMC,
and cisplatin are similarly eﬀective in establishing the FA
diagnosis in a chromosomal breakage assay. According to
a single comparative study, MMC appeared slightly more
suitable for the assessment of lymphocyte mosaicism [14]. It
should be pointed out that, unlike DEB and cisplatin, MMC
requires metabolic activation in order to become active as a
cross-linking agent. If metabolic activation were a variable
parameter, this may be considered a disadvantage for MMC
and an argument in favour of choosing cisplatin as the
diagnostic cross-linker.
B.2.5. Conversion of Interchanges into Break Events. Although
the idea of two breaks underlying each interchange between
two chromosomes (often referred to as “radial”) has been
considered commonplace in the genetic toxicology literature,
this hypothesis is challenged by the observations of Godthelp
et al. [43], who found the frequency of interchanges to
increase linearly with drug dosage (rather than exponen-
tially), implying single-hit rather than two-hit kinetics. If the
single-hit principle were to be accepted, this would change
the conversion factor for the quantification of interchange
aberrations into break events from 2 to 1; however, adopting
a conversion factor of 1 would not aﬀect the general principle
of the FA diagnosis, as described here.
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